Mucormycosis Study

Not Applicable

• Conditions: Health Condition 1: - Health Condition 2: A00-B99- Certain infectious and parasitic diseases

• Registration Number: CTRI/2021/07/035281
• Lead Sponsor: Datar Cancer Genetics Private Limited

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 17 October 2022

Recruitment & Eligibility

• Status: Closed to Recruitment of Participants
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

�High risk patients (patients with prolonged severe neutropenia, receiving corticosteroids or T-cell suppressor, recipients of allogeneic Hematopoietic stem-cell transplantation (HSCT), or inherited severe immunodeficiency)

�Patients with other predisposing factors of invasive mould disease (Uncontrolled blood sugars, known diabetic on steroids , Acquired immunodeficiency syndrome (AIDS), haematological malignancies or solid tumours, prolonged Intensive Care Unit, or hospital stay abnormal D Dimer test).

�Patients already diagnosed with probable or proven mucormycosis irrespective of underlying conditions, including patients referred from other centers.

Exclusion Criteria

�Presence of any medical condition that would not allow collection of blood samples for the Real-time polymerase chain reaction test.

�History of documented, successfully treated, prior Mucormycosis.

Study & Design

• Study Type: Observational
• Study Design: Not specified